🇺🇸 Ramipril and hydrochlorothiazide in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 17

Most-reported reactions

1. Acute Respiratory Failure — 3 reports (17.65%)
2. Acidosis — 2 reports (11.76%)
3. Acute Pulmonary Oedema — 2 reports (11.76%)
4. Drug Reaction With Eosinophilia And Systemic Symptoms — 2 reports (11.76%)
5. Idiosyncratic Drug Reaction — 2 reports (11.76%)
6. Leukopenia — 2 reports (11.76%)
7. Aphasia — 1 report (5.88%)
8. Blood Glucose Increased — 1 report (5.88%)
9. Cardiac Failure — 1 report (5.88%)
10. Cns Ventriculitis — 1 report (5.88%)

Source database →

Frequently asked questions

Is Ramipril and hydrochlorothiazide approved in United States?

Ramipril and hydrochlorothiazide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ramipril and hydrochlorothiazide in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.